Kimberly McBennett

877 total citations · 1 hit paper
15 papers, 293 citations indexed

About

Kimberly McBennett is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Atomic and Molecular Physics, and Optics. According to data from OpenAlex, Kimberly McBennett has authored 15 papers receiving a total of 293 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 3 papers in Epidemiology and 2 papers in Atomic and Molecular Physics, and Optics. Recurrent topics in Kimberly McBennett's work include Cystic Fibrosis Research Advances (13 papers), Neonatal Respiratory Health Research (5 papers) and Respiratory viral infections research (2 papers). Kimberly McBennett is often cited by papers focused on Cystic Fibrosis Research Advances (13 papers), Neonatal Respiratory Health Research (5 papers) and Respiratory viral infections research (2 papers). Kimberly McBennett collaborates with scholars based in United States. Kimberly McBennett's co-authors include Pamela B. Davis, Michael W. Konstan, Chris A. Flask, Shannon Donnola, Mitchell L. Drumm, Thomas J. Sferra, Samya Z. Nasr, Rose Gubitosi‐Klug, Beth A. Kaminski and MaryAnn O’Riordan and has published in prestigious journals such as Radiology, American Journal of Physiology-Gastrointestinal and Liver Physiology and Pediatric Pulmonology.

In The Last Decade

Kimberly McBennett

14 papers receiving 289 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study

2023 82 citations Steven M. Rowe, Jonathan B. Zuckerman et al. Journal of Cystic Fibrosis profile →

Peers

Countries citing papers authored by Kimberly McBennett

Since Specialization

Citations

This map shows the geographic impact of Kimberly McBennett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly McBennett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly McBennett more than expected).

Fields of papers citing papers by Kimberly McBennett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly McBennett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly McBennett. The network helps show where Kimberly McBennett may publish in the future.

Co-authorship network of co-authors of Kimberly McBennett

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly McBennett. A scholar is included among the top collaborators of Kimberly McBennett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly McBennett. Kimberly McBennett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor 2025 ·Annals of the American Thoracic Society ·Scott D. Sagel, (unknown), Brandie D. Wagner, Jing Xie, Sonya L. Heltshe, (unknown), Preston E. Bratcher, Jennifer L. Taylor‐Cousar, Alexandra Wilson, Kimberly McBennett, Sarah J. Morgan, Pradeep K. Singh, David P. Nichols, Andrea Kelly, George M. Solomon, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
2	Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat‐soluble vitamin levels and association with body mass index 2024 ·Pediatric Pulmonology ·(unknown), Kimberly McBennett, Senthilkumar Sankararaman, (unknown), Krithika Sundaram, Nori Minich, (unknown), (unknown)	12
3	Lung T1 MRI assessments in children with mild cystic fibrosis lung disease 2024 ·Pediatric Pulmonology ·Clement L. Ren, Samya Z. Nasr, James E. Slaven, Aparna Joshi, Maryam Ghadimi Mahani, Charles Clem, Matthew N. Cooper, (unknown), (unknown), (unknown), Jennifer L. Nicholas, (unknown), Kimberly McBennett, Chris A. Flask	1
4	Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study breakdown → 2023 ·Journal of Cystic Fibrosis ·Steven M. Rowe, Jonathan B. Zuckerman, Daniel Dorgan, Jorge Lascano, Karen McCoy, Manu Jain, Michael S. Schechter, (unknown), (unknown), Noah Lechtzin, Kimberly McBennett, (unknown), Cynthia D. Brown, Theodore G. Liou, Kelvin D. MacDonald, Samya Z. Nasr, (unknown), (unknown), Eric B. Meltzer, Ann Barbier	82
5	439 Neurologic and mental health adverse events with CFTR modulator therapies at a cystic fibrosis center 2023 ·Journal of Cystic Fibrosis ·(unknown), Kimberly McBennett, (unknown), (unknown)	1
6	WS05.06 Phase 1/2a randomized, double-blind, placebo-controlled study: safety, Pk, and Efficacy outcome measures of inhaled Gallium Citrate (AR-501) in P Aeruginosa infected Cystic Fibrosis patients 2023 ·Journal of Cystic Fibrosis ·(unknown), Noah Lechtzin, Steven R. Boas, Tahuanty Peña, Kimberly McBennett, Jane E. Gross, Daniel Dorgan, Letha H. Couch, Lucas R. Hoffman, Milene T. Saavedra, Katherine B. Hisert, (unknown), (unknown), (unknown), (unknown), (unknown), Jennifer Woo, (unknown), Hasan S. Jafri	1
7	Toward a Broader Understanding of Cystic Fibrosis Epidemiology and Its Impact on Clinical Manifestations 2022 ·Clinics in Chest Medicine ·Kimberly McBennett, Pamela B. Davis	4
8	Rapid B₁-Insensitive MR Fingerprinting for Quantitative Kidney Imaging 2021 ·Radiology ·(unknown), (unknown), (unknown), (unknown), (unknown), Kimberly McBennett, (unknown), Mitchell L. Drumm, (unknown), Mark A. Griswold, Dan Ma, Katherine MacRae Dell, Chris A. Flask, Yong Chen	16
9	Increasing life expectancy in cystic fibrosis: Advances and challenges 2021 ·Pediatric Pulmonology ·Kimberly McBennett, Pamela B. Davis, Michael W. Konstan	92
10	Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies 2021 ·Journal of Cystic Fibrosis ·Kimberly McBennett, (unknown), (unknown), Maryam Ghadimi Mahani, Jaime F. Mata, Alexander J. Towbin, Senthilkumar Sankararaman, Mitchell L. Drumm, Xin Yu, Clement L. Ren, Samya Z. Nasr, (unknown), Chris A. Flask	8
11	544: Safety and tolerability of single and repeat doses of MRT5005, an inhaled CFTR mRNA replacement therapy, in adult CF patients 2021 ·Journal of Cystic Fibrosis ·Steven M. Rowe, Daniel Dorgan, Jorge Lascano, Jonathan B. Zuckerman, Karen McCoy, Mamta K. Jain, Martin T. Schechter, (unknown), (unknown), Noah Lechtzin, Kimberly McBennett, (unknown), Carrie Brown, Theodore G. Liou, (unknown), Samya Z. Nasr, (unknown), E Meltzer, Ann Barbier	2
12	529: A phase 1b, randomized, double-blind, placebo-controlled, dose-escalation trial of CB-280, an arginase inhibitor, in patients with cystic fibrosis 2021 ·Journal of Cystic Fibrosis ·Steven R. Boas, Scott H. Donaldson, Kimberly McBennett, Theodore G. Liou, Judie A. Howrylak, Laura E. Johnson, Charlotte C. Tenebäck, Allen J. Dozor, G. Sawicki, (unknown), (unknown), (unknown), (unknown), Susan M. Carroll, Keith Orford, Emil Kuriakose, Joel Mermis	2
13	Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients 2019 ·World Journal of Hepatology ·(unknown), Shannon Donnola, Chris A. Flask, Rose Gubitosi‐Klug, MaryAnn O’Riordan, Kimberly McBennett, Thomas J. Sferra, Beth A. Kaminski	36
14	Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3 2018 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·(unknown), Calvin U. Cotton, Fraser J. Moss, (unknown), (unknown), Thomas J. Kelley, (unknown), Anjum Jafri, Mitchell L. Drumm, Walter F. Boron, Robert C. Stern, Kimberly McBennett, Craig A. Hodges	22
15	Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients 2015 ·Journal of Cystic Fibrosis ·Shannon Donnola, Elliott C. Dasenbrook, (unknown), Lan Lŭ, Karishma Gupta, (unknown), Xin Yu, James F. Chmiel, Kimberly McBennett, Michael W. Konstan, Mitchell L. Drumm, Chris A. Flask	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact